KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $4.9 billion.

  • Vertex Pharmaceuticals' Cash & Equivalents fell 571.84% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year decrease of 571.84%. This contributed to the annual value of $4.6 billion for FY2024, which is 5593.06% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Cash & Equivalents stood at $4.9 billion for Q3 2025, which was down 571.84% from $5.0 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Cash & Equivalents' 5-year high stood at $11.1 billion during Q3 2023, with a 5-year trough of $4.6 billion in Q4 2024.
  • In the last 5 years, Vertex Pharmaceuticals' Cash & Equivalents had a median value of $6.8 billion in 2021 and averaged $7.4 billion.
  • In the last 5 years, Vertex Pharmaceuticals' Cash & Equivalents skyrocketed by 7544.05% in 2021 and then crashed by 5593.06% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash & Equivalents (Quarter) stood at $6.8 billion in 2021, then soared by 54.58% to $10.5 billion in 2022, then decreased by 1.28% to $10.4 billion in 2023, then tumbled by 55.93% to $4.6 billion in 2024, then grew by 8.1% to $4.9 billion in 2025.
  • Its Cash & Equivalents stands at $4.9 billion for Q3 2025, versus $5.0 billion for Q2 2025 and $4.7 billion for Q1 2025.